RESEARCH REPORT ON PIRAMAL PHARMA LIMITED
Piramal Pharma Limited is an India-based pharmaceutical company, which offers a portfolio of differentiated pharma products across a domestic and global distribution network. The Company has approximately 17 global facilities and a global distribution network in over 100 countries. The Company’s subsidiaries include Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business, and the India consumer healthcare business selling over-the-counter products. PPS offers end-to-end development and manufacturing solutions through a globally integrated network of facilities across the drug life cycle to generic companies. PCC’s complex hospital product portfolio includes inhalation anesthetics, intrathecal therapies for spasticity and pain management, injectable pain, anesthetics, injectable anti-infectives, and other therapies.
COMPANY PROFILE
Piramal Group
Type Conglomerate
Founded 1984; 39 years ago
Headquarters Mumbai, Maharashtra, India
Area served Worldwide
Key people • Ajay Piramal (Chairperson, Managing Director & Chief Executive Officer)
• Swati Piramal (Vice Chairperson)
Services • Pharmaceutical
• Healthcare
• Life sciences
• Financial services
• Capital
• Real estate
Revenue ₹14,710 crore (US$1.8 billion) (FY22)
Operating income
₹6,500 crore (US$810 million) (FY22)
Net income
₹1,923.11 crore (US$240 million) (FY22)
Subsidiaries
• Piramal Glass
• Piramal Enterprises
• Piramal Pharma
• Piramal Realty
• Piramal Steel
• Piramal Foundation
Website www.piramal.com
FUNDAMENTALS
SHAREHOLDING
FINANCIALS
REVENUE
NET PROFIT
EPS
BVPS
ROE
DEBT TO EQUITY
TECHNICAL ANALYSIS
BUY PPL PHARMA MKT 134 TGT 154, 175 SL 114 (1-3 MONTH)
RATIO ANALYSIS
Disclaimer: This research report is prepared by Shyam Advisory Limited, while making this report we have taken data from available sources and there may be errors in the data shown. We do not guarantee the accuracy of data and recommendation given in this report. Recommendation is for information purpose only. Registration granted by SEBI, membership of BASL and certification from NISM in no way guarantee performance of the Intermediary or provides any assurance of returns to investors.
“Investment in Securities market is subject to market risks. Read all the related documents carefully before investing.”